TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03529279
Drug: NCCN Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy.
Study: NCT00490620
Drug: Combination antiviral therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine 300mg and lamivudine 150mg BID for 6 months
Study: NCT05066035
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.
Study: NCT02145598
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
Study: NCT00480870
Drug: donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
Study: NCT00369967
Drug: NuvaRing
Normalized name: NuvaRing
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiation of NuvaRing for contraception
Study: NCT00453180
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
Study: NCT00599638
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75mg bid titrating to 150mg bid on day 4
Study: NCT00599638
Drug: pregabalin/PF-00489791
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
Study: NCT00519662
Drug: SNS-314
Normalized name: SNS-314
DrugBank: SNS-314 (DB06134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1
Study: NCT04474314
Drug: IMR-687
Normalized name: IMRCs
DrugBank: Human Embryonic Stem Cell-derived M Cell (DB15734)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of once daily IMR-687
Study: NCT03006887
Drug: lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenvatinib capsules
Study: NCT03006887
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab intravenous infusion
Study: NCT01300988
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant (Emend®) 375 mg daily for 14 days
Study: NCT01300988
Drug: Aprepitant placebo
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant(Emend®) placebo for 14 days
Study: NCT00804843
Drug: Atorvastatin/niacin extended-release
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
Study: NCT00804843
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
Study: NCT00536848
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003129
Drug: valrubicin
Normalized name: Valrubicin
DrugBank: Valrubicin (DB00385)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00462748
Drug: Comparator: atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
Study: NCT00556270
Drug: Matrifen
Normalized name: matrine
DrugBank: Oxymatrine (DB16276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
Study: NCT04237246
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 hour long acting advegraf
Study: NCT00924404
Drug: Xylitol
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% solution for sinus rinse
Study: NCT00924404
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline for sinus rinse
Study: NCT03898128
Drug: Anti-CD22 Immunotoxin
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clinical data (treatment, survival, adverse events) of patients treated with anti-CD22 immunoconjugates from 2014 will be collected
Study: NCT00556413
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00556413
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02424045
Drug: BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)
Normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
Study: NCT02163421
Drug: Vedolizumab SC
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab injection, for subcutaneous use (vedolizumab SC)
Study: NCT02163421
Drug: Vedolizumab IV
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab injection, for intravenous use (vedolizumab IV)
Study: NCT00372541
Drug: ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01344720
Drug: oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy).
Study: NCT01424228
Drug: prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prucalopride 2 mg daily before breakfast~1 mg for subjects \>65 years; in case of insufficient response 2 mg at week 2 or week 4
Study: NCT00085332
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01270256
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
Study: NCT01742689
Drug: Desmopressin intranasal spray
Normalized name: desmopressin Nasal Spray
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 microgram per puff, 40 microgram is Descript
Study: NCT01867138
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01867138
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02964585
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg
Study: NCT03323866
Drug: Budesonide 0.5 MG/ML
Normalized name: budesonide 0.5 MG/ML
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
Study: NCT03323866
Drug: Mometasone nasal spray
Normalized name: mometasone Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone 50 mcg/spray 2 sprays twice daily
Study: NCT04040621
Drug: Ceftazidime-avibactam
Normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.
Study: NCT00169091
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
Study: NCT00169091
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
Study: NCT00000466
Drug: estrogens, conjugated
Normalized name: ESTROGENS, CONJUGATED
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000466
Drug: medroxyprogesterone
Normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000466
Drug: progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000466
Drug: estrogen replacement therapy
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02434965
Drug: HPDSC
Normalized name: Hydroxyprogesterone Depo-Subq Contraceptive
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
Study: NCT02434965
Drug: Cord blood
Normalized name: CORD BLOOD
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
Study: NCT03979599
Drug: magnesium sulphate& levobupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: magnesium sulphate\& levobupivacaine
Study: NCT03979599
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: levobupivacaine
Study: NCT01722656
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00932165
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal.
Study: NCT01440881
Drug: Nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infuses at 0.01MCG/KG/min for 48 hours
Study: NCT00291148
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00327990
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00291148
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03280173
Drug: tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bioavailability study
Study: NCT02683564
Drug: Remicade
Normalized name: Remicade
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: monoclonal antibody against TNF-alpha
Study: NCT04397328
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine vs placebo (1:1 design) double blind intervention
Study: NCT00326248
Drug: GW679769 (casopitant)
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01943240
Drug: Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01943240
Drug: 10 cc of 0.375% ropivacaine pectoral nerve block
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01608373
Drug: Intravenous lidocaine injection
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
Study: NCT01608373
Drug: Intraperitoneal lidocaine irrigation group
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
Study: NCT01608373
Drug: Intravenous normal saline injection
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Study: NCT00569868
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000.
Study: NCT00002580
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002580
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002580
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02667470
Drug: Solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT05383534
Drug: Propofol Injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol injections were used for the induction of anesthesia according to the body weight of the patients.
Study: NCT02711202
Drug: Remicade
Normalized name: Remicade
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
Study: NCT02711202
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
Study: NCT02711202
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
Study: NCT03346096
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fixed dose 5mg/kg on days -7-6
Study: NCT02910102
Drug: RVT-101 35 mg
Normalized name: RVT-801
DrugBank: ACG-801 (DB17659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVT-101 once daily, oral, 35-mg tablets
Study: NCT04303299
Drug: Oral
Normalized name: Doral
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti virus treatment
Study: NCT03401060
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
Study: NCT02540265
Drug: N1539
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01105377
Drug: entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01105377
Drug: azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT01590654
Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
Study: NCT02605174
Drug: Lasmiditan 50 mg
Normalized name: lasmiditan 50 MG
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
Study: NCT02399137
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02399137
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03131882
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
Study: NCT03131882
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
Study: NCT00971295
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
Study: NCT00971295
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00240383
Drug: Muraglitazar
Normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03271905
Drug: salbutamol sulfate and ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
Study: NCT02861482
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
Study: NCT02861482
Drug: Hemabate
Normalized name: Hemabate
DrugBank: Carboprost tromethamine (DB00429)
Approvals — FDA: no, EMA: no, PMDA: no
Description: using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
Study: NCT02861482
Drug: Duratocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon